By Michael Phillips | MDBayNews Staff
Maryland Attorney General Anthony G. Brown has joined a multistate lawsuit challenging a recent federal action that seeks to limit taxpayer-funded gender-transition medical interventions for minors. Framed by supporters as a defense of “evidence-based, lifesaving care,” the suit instead places Maryland squarely at odds with a growing body of international medical caution, recent Supreme Court precedent, and a national reassessment of how far government should go in subsidizing irreversible medical decisions for children.
The lawsuit targets a December 18 declaration issued by Robert F. Kennedy Jr., head of the U.S. Department of Health and Human Services. That declaration warned that puberty blockers, cross-sex hormones, and related interventions for minors are “unsafe and ineffective,” citing low-quality evidence and unresolved long-term risks. It further signaled that providers offering such treatments to children could face exclusion from Medicare and Medicaid participation.
Brown and attorneys general from 18 other Democratic-led states, along with the District of Columbia, filed suit in federal court in Oregon, arguing that HHS overstepped its authority and violated the Administrative Procedure Act by issuing what they characterize as a de facto rule without notice-and-comment. They also claim the action interferes with states’ rights to regulate medicine and coerces providers into halting care.
But stripped of rhetoric, the case highlights a deeper divide: whether government should continue underwriting experimental medical practices for minors amid unresolved scientific doubts—or whether restraint is warranted until stronger evidence exists.
Science Is Moving—Maryland Isn’t
For years, U.S. debate over youth gender medicine has been insulated from developments overseas. That insulation is cracking. Independent reviews commissioned by governments in the United Kingdom, Sweden, Finland, Norway, and other European nations have consistently found the evidence supporting medical gender interventions for minors to be of low or very low certainty. England’s 2024 Cass Review concluded there is no reliable proof that puberty blockers or hormones improve long-term mental health outcomes for children and recommended sharply restricting their use to research settings.
These were not conservative governments reacting to politics; they were progressive health systems responding to data gaps, methodological weaknesses, and mounting ethical concerns.
By contrast, Maryland has doubled down. The state mandates Medicaid coverage for youth gender interventions and spent roughly $1.7 million on such services in 2024. Gov. Wes Moore’s administration has cast any pullback as discriminatory—even as international peers pivot toward psychotherapy-first models and tighter safeguards.
Courts Have Also Shifted
The lawsuit also ignores the legal terrain reshaped this year by the U.S. Supreme Court. In June, the Court upheld Tennessee’s ban on puberty blockers and hormones for minors, ruling that states may regulate these treatments under ordinary “rational basis” review given ongoing medical uncertainty. The majority explicitly declined to extend earlier employment-discrimination reasoning into youth medical care, deferring instead to legislatures weighing risks and benefits.
That ruling has already led to the unraveling of lower-court decisions that once treated youth gender medicine as constitutionally protected. Against that backdrop, Maryland’s insistence that the science is settled—and that federal caution is unlawful—looks increasingly disconnected from reality.
Procedure vs. Substance
To be clear, the states’ lawsuit is not frivolous. Administrative-law challenges often succeed on procedural grounds, and a judge may well rule that HHS should have gone through formal rulemaking. But winning on process would not resolve the underlying question: whether it is prudent or ethical to compel federal taxpayers to subsidize treatments for children that many experts now consider experimental.
That is the question Maryland’s leaders avoid.
Who Is Being Protected?
Supporters of the lawsuit argue that restricting funding harms vulnerable youth and interferes with family and doctor decision-making. Critics counter that aggressive “affirmation-first” medical models have sidelined parental caution, rushed minors toward irreversible outcomes, and treated unresolved distress with pharmaceuticals instead of therapy.
A center-right view does not deny the suffering of dysphoric youth. It simply asks whether compassion requires more medicine—or better evidence.
By suing to block federal restraint, Maryland has chosen ideology over caution and litigation over reflection. As other democracies pause, reassess, and recalibrate, Maryland is racing to lock in a medical model the rest of the world is quietly questioning.
That may win applause in progressive circles. It may even win a procedural skirmish in court. But it does not answer the harder question facing parents, doctors, and taxpayers alike: when it comes to children, shouldn’t uncertainty counsel restraint?
Keep MDBayNews Reporting Free
MDBayNews exists to help Marylanders understand decisions made by state and local leaders — especially when those decisions affect daily life, rights, and public services.
If this article helped clarify what’s happening or why it matters, reader support makes it possible to keep publishing clear, independent reporting like this.
Have a tip or documents to share?
We review submissions carefully and confidentially. Anonymous tips are welcome when appropriate.
Discover more from Maryland Bay News
Subscribe to get the latest posts sent to your email.